Tuberculosis (TB), humanity’s ancient and most lethal infectious adversary, is making an alarming comeback. Once viewed as a conquerable foe, this persistent bacterial infection is now quietly resurfacing across the United States and globally, challenging decades of progress and sparking urgent calls for renewed public health action. While hopes for its eradication once ran high, recent data reveals a concerning rise, signaling that the world’s deadliest infection is far from defeated.
The Unseen Killer: Understanding Tuberculosis
For thousands of years, Mycobacterium tuberculosis has plagued human populations, earning its grim title as the world’s leading infectious killer. Scientifically identified in 1882, TB has claimed over a billion lives, surpassing the combined toll of smallpox, malaria, HIV/AIDS, cholera, and the flu. This highly contagious bacterium primarily attacks the lungs, though it can devastate any organ with deadly efficiency. It spreads through microscopic airborne droplets released when an infected person coughs, sneezes, or even breathes.
Interestingly, TB plays a complex game with its hosts. Many infected individuals develop latent TB, carrying the bacteria without falling ill or being contagious. An estimated 13 million Americans harbor latent TB, and while 90% may never develop active disease, 5-15% can progress to a symptomatic, contagious form if untreated. Active TB manifests with a range of severe symptoms, including a chronic, hacking cough, chest pain, and night sweats. If diagnosed, it’s treatable with antibiotics, but without intervention, it can be fatal.
A Dangerous Complacency: How Success Led to Decline
The mid-20th century brought a wave of optimism. With the advent of antibiotics in the 1950s, TB rates plummeted. Deaths from the disease in the US fell by a staggering 90% by the late 1980s. This remarkable success, however, bred a perilous overconfidence. Convinced TB was headed for the history books, the US Congress significantly cut direct federal funding for many TB programs in 1972.
Aside from a brief spike in the early 1990s, the downward trend continued for decades. But around 2021, a new and worrying pattern emerged. Data from the US Centers for Disease Control and Prevention (CDC) confirms a year-over-year increase in TB cases between 2021 and 2024, including a notable 7.9% jump in case counts in 2024. Despite the US still maintaining one of the lowest incidence rates globally, these figures are a stark warning that something critical is shifting.
Outbreaks and Alarms: A National and Global Trend
The resurgence isn’t confined to statistics. In 2024, Kansas experienced one of its largest TB outbreaks in modern history, with at least 68 active and 91 latent cases. More recently, outbreaks at high schools in San Francisco, Long Island, New York, and Seattle have highlighted the problem in unexpected settings. For example, an investigation at Archbishop Riordan High School in San Francisco identified at least three active cases and over 30 latent infections among students and staff, necessitating mandatory testing and contact tracing. This signifies that even wealthy nations with developed healthcare systems are vulnerable.
Across the Atlantic, the UK reported its sharpest single-year increase in TB cases since the 1990s in 2024, prompting fears it might lose its low-incidence status. Globally, the World Health Organization (WHO) reported in late 2025 that TB cases had risen again in 2024, reaching their highest recorded levels. This pattern suggests a systemic problem extending far beyond isolated incidents or national borders.
Unraveling the Causes: A Multi-Layered Crisis
The factors driving this disturbing tuberculosis resurgence are complex and interconnected:
COVID-19 Aftermath: The pandemic overwhelmed healthcare systems, diverting resources and attention away from other diseases like TB. The result was delayed diagnoses, sicker patients, and increased transmission risks.
Public Health Disinvestment: Experts describe the rise of TB as a “canary in a coalmine,” reflecting cracks in national public health systems due to chronic underfunding and complacency.
Social Determinants of Health: Often called a “social disease of poverty,” TB thrives in conditions of overcrowded housing, malnutrition, and precarious working environments. As living standards decline in many regions, the bacterium finds fertile ground, much like it did in Victorian London.
Funding Cuts to Global Health: Political decisions have a profound impact. In 2025, proposed cuts to US global health and humanitarian programs, such as the Global Fund, raised grave concerns. One analysis warned these cuts could lead to millions of additional pediatric TB cases and hundreds of thousands of child deaths globally, especially in low-income countries in Africa and Southeast Asia.
Antibiotic Resistance: The arduous nature of TB treatment—requiring multiple antibiotics for months—contributes to the rise of drug-resistant TB, which is far harder and more expensive to treat, costing upwards of $154,000 per person in the US.
Global Mobility: The world is more connected than ever. Infectious diseases do not respect national borders, meaning an increase in TB cases anywhere can pose a threat everywhere.
In the US, the disease disproportionately impacts marginalized communities, including immigrant populations and individuals in congregate settings like prisons and homeless shelters, where overcrowding and poor ventilation facilitate spread.
Hope on the Horizon: New Science and Collaborative Efforts
Despite the formidable challenges, there is hope. Scientists are intensely focused on understanding Mycobacterium tuberculosis to develop better tools. Recent international research has uncovered critical insights into how experimental antibiotic compounds like ecumicin, ilamycins, and cyclomarins target a vital protein recycling system within the bacterium called the ClpC1–ClpP1P2 complex. Disrupting this complex severely weakens the bacterium, offering promising avenues for designing more precise and effective treatments, particularly against drug-resistant strains.
Additionally, researchers at institutions like the University of Utah are investigating how factors like global air pollution impact TB transmission and how M. tuberculosis evades immunity, aiming to inform future vaccine and drug development. Crucially, the commitment to tackling TB globally remains, with organizations like the WHO pushing for continued multilateral cooperation, as exemplified by the historic WHO Pandemic Agreement adopted in 2025.
Ending TB requires sustained investment in research, better diagnostics, improved treatments, and effective adult vaccines. It demands strengthening public health infrastructure, addressing social inequities, and fostering global collaboration. As Dr. Paul Farmer wisely stated, “When it comes to global health, there is no ‘them’… only ‘us’.”
Frequently Asked Questions
What is the difference between latent and active tuberculosis, and why is this distinction important?
Latent tuberculosis (LTBI) means an individual is infected with the Mycobacterium tuberculosis bacteria but does not exhibit symptoms and is not contagious. The bacteria remain dormant in the body. However, 5-15% of people with latent TB can develop active TB disease in their lifetime, at which point they become symptomatic and can transmit the infection. This distinction is crucial for public health: treating latent TB with preventative therapy (TPT) can prevent future active cases, reducing spread and saving significant healthcare costs, as active TB treatment is much more expensive and complex.
What are the main factors contributing to the recent tuberculosis resurgence in the US and globally?
The tuberculosis resurgence stems from multiple interconnected issues. Globally, the COVID-19 pandemic significantly disrupted healthcare systems, leading to delayed TB diagnoses and treatments. Public health systems worldwide, including in the US, have also suffered from chronic underfunding and complacency, leaving them ill-prepared. Furthermore, TB is often a “social disease of poverty,” thriving in overcrowded conditions, with poor nutrition and inadequate healthcare access, which have worsened in many regions. Cuts to global health initiatives and the rise of drug-resistant strains also exacerbate the problem, highlighting the need for robust, equitable public health strategies.
How can individuals protect themselves and support efforts to combat the resurgence of tuberculosis?
While the general incidence of TB in the US is relatively low, individuals can take proactive steps. If you have been exposed to someone with active TB, or if you belong to a high-risk group (e.g., immunocompromised, living in congregate settings, or from a high-incidence country), consult a healthcare provider for screening. Supporting public health initiatives through awareness, advocacy, and ensuring marginalized communities have access to testing and treatment without fear is vital. On a global scale, advocating for sustained funding for research into new vaccines and better diagnostics, as well as strengthening international health collaborations, are crucial for effective TB eradication.
